Anlon Healthcare Bets On Acquisition-Led Growth, Targets 25% EBITDA Margin In H1

Anlon Healthcare Managing Director Punit Rasadiya told NDTV Profit that the company is on track to achieve its sales target for the first quarter while maintaining its EBITDA and profit margins. He said the recent acquisition has strengthened the company's backward integration capabilities, adding that Anlon expects to achieve an EBITDA margin of 25% in the first half of the fiscal year. Rasadiya also said the company plans to commercialise a molecule by the third and fourth quarters and highlighted that Anlon acquired a formulations facility last month. He further clarified that the company has no plans to dilute any additional stake in FY27.